USGrantedDelivery formulation

Lysergide (LSD) orally disintegrating tablet formulations

US-12036220-B2

Bibliographic data

Patent number
US-12036220-B2
Jurisdiction
US
Status
Granted
Type
Delivery formulation
Priority date
19 August 2021
Filing date
3 April 2023
Grant date
16 July 2024

Compounds claimed

LSD
classic psychedelic
→

Assignees

Definium Therapeutics
Definium Therapeutics (formerly Mind Medicine / MindMed) is a late-stage clinical biopharmaceutical company headquartered in New York, founded in 2019 and rebranded in January 2026. Led by CEO Robert Barrow, the company applies scientific rigor to psychedelic-derived molecules to develop accessible, rapidly-acting psychiatric treatments. Its lead asset, DT120 ODT (formerly MM-120) — a pharmaceutically optimised formulation of lysergide D-tartrate (LSD) as an orally disintegrating tablet — has received FDA Breakthrough Therapy Designation for generalised anxiety disorder (GAD) and delivered compelling Phase 2b results: 65% clinical response rate and 48% remission at 12 weeks following a single dose. Three Phase 3 trials are currently underway: Voyage and Panorama (GAD) and Emerge (MDD, fully enrolled). Topline data from all three studies is expected in 2026, potentially positioning Definium for the first-ever FDA approval of an LSD-derived therapy. A second pipeline asset, DT402 (formerly MM402) — an MDMA-related compound — is in Phase 1 development for autism spectrum disorder.
→

Prior art & evidence

Prior art and related research that speaks to this patent, curated from the Blossom database.

Analysis

MM120 is lysergide, LSD, formulated as an orally disintegrating tablet. As with esketamine, the value sits less in the molecule, long known, than in the formulation and the clinical dataset behind it.

MindMed, now operating as Definium Therapeutics, has taken the compound into phase 3 for both generalised anxiety disorder and major depression. The trials below are that programme.